Wait what? The way I read this, is that the FDA can issue another Voucher?
Trofinetide has been granted Fast Track Status and Orphan Drug Designation for the treatment of Rett syndrome in the United States. An NDA with Orphan Drug Designation is eligible for priority review. Trofinetide has also been granted Rare Pediatric Disease (RPD) designation by the FDA. With such designation, Acadia expects to be awarded a Priority Review Voucher if the NDA is approved.
Why would they type "to be awareded a Priority Review Voucher"? I thought they already have one for Trofinetide?
Wait what? The way I read this, is that the FDA can issue...
-
- There are more pages in this discussion • 672 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.09 |
Change
-0.260(2.11%) |
Mkt cap ! $1.545B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.20 | $12.04 | $795.7K | 65.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 266 | $12.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.10 | 224 | 8 |
View Market Depth
| Last trade - 11.37am 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |